Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Breast
Descriptor: Animal models


Reference Number: 19
Fan, S. et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 17, 131-41 (1998).
PubMed link      E-mail link

Reference Number: 20
Farinelle, S. et al. Characterization of biological features and chemosensitivity of a new experimental lung metastasis model originating from the MXT mouse mammary adenocarcinoma. Anticancer Res 19, 1171-80 (1999).
PubMed link      E-mail link

Reference Number: 21
Firon, M. et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 19, 2386-97 (2000).
PubMed link      E-mail link

Reference Number: 24
Lamszus, K. et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest 76, 339-53 (1997).
PubMed link      E-mail link

Reference Number: 25
Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. & Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 97, 2872-7 (1996).
PubMed link      E-mail link

Reference Number: 26
Rosen, E. M. et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 57, 706-14 (1994).
PubMed link      E-mail link

Reference Number: 27
Shaharabany, M. et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res 61, 4873-8 (2001).
PubMed link      E-mail link

Reference Number: 28
Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94, 701-6 (1997).
PubMed link      E-mail link

Reference Number: 217
Gallego, M.I., Bierie, B. & Henninghausen, L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways.  Oncogene 22:8498-508 (2003).
PubMed link      E-mail link

Reference Number: 294
Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73 (2004)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 346
Welm AL, Kim S, Welm BE, Bishop JM. MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A. 102, 4324-9 (2005)
PubMed link      E-mail link

Reference Number: 358
Khoury H, Naujokas MA, Zuo D, Sangwan V, Frigault MM, Petkiewicz S, Dankort DL, Muller WJ, Park M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell. 16 550-61(2005)
PubMed link      E-mail link

Reference Number: 365
Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674-9 (2005)
PubMed link      E-mail link

Reference Number: 368
Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 66, 3452-5 (2006)
PubMed link      E-mail link

Reference Number: 463
Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 16, 723-8 (2005)
PubMed link      E-mail link

Reference Number: 964
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1243
Accornero P, Miretti S, Bersani F, Quaglino E, Martignani E, Baratta M. Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells. PLoS One. 7, e44982 (2012)
PubMed link      E-mail link

Reference Number: 1267
Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene. 32, 1428-40 (2013)
PubMed link      E-mail link

Reference Number: 1340
Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A. 110, E1301-10 (2013)
PubMed link      E-mail link

Reference Number: 1359
Regan Anderson TM1, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res. 73, 5810-20 (2013)
PubMed link      E-mail link

Reference Number: 1451
Sundaram S1, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA, Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat. 142, 489-503 (2013)
PubMed link      E-mail link

Reference Number: 1568
Maroni P, Bendinelli P, Matteucci E, Locatelli A, Nakamura T, Scita G, Desiderio MA. Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification. Cell Death Dis. 5, e1005 (2014)
PubMed link      E-mail link

Reference Number: 1570
Holland JD, Györffy B, Vogel R, Eckert K, Valenti G, Fang L, Lohneis P, Elezkurtaj S, Ziebold U, Birchmeier W. Combined Wnt/ß-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep. 5, 1214-27 (2013)
PubMed link      E-mail link

Reference Number: 1602
Qin Y, McAllister SS. SPSB1 may have MET its match during breast cancer recurrence. Cancer Discov. 4, 760-1 (2014)
PubMed link      E-mail link